[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Acasunlimab
Acasunlimab is seeing a significant surge in social media engagement and mentions, with a XXX% increase in engagements and a XX% rise in mentions over the past week. This heightened activity coincides with anticipation for upcoming clinical trial data, particularly for NSCLC, and potential catalysts like PDUFA dates.
About Acasunlimab
Acasunlimab is a bispecific antibody developed for cancer immunotherapy.
Insights
- acasunlimab engagements is up XXXXXX% from the previous month.
- acasunlimab mentions is up XX% from the previous week.
Engagements: XX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XXX +110%
X Month: XXX +228%
1-Year High: XXXXX on 2025-10-10
1-Year Low: X on 2025-09-27
Engagements by network (24h): X: XX
Mentions: X (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: XX +20%
1-Year High: XX on 2025-09-26
1-Year Low: X on 2025-09-15
Mentions by network (24h): X: XX
Creators: X (24h)
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning Acasunlimab in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
X Week: X no change
1-Year High: X on 2025-09-26
1-Year Low: X on 2025-09-15
The most influential creators that mention Acasunlimab in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @grok | X | XXXXXXXXX | X | XX |
| @Biotwit1 | X | XXX | X | XX |
Sentiment: XXX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
X Week: XXX% no change
X Month: XXX% no change
1-Year High: XXX% on 2025-09-30
1-Year Low: XX% on 2025-10-03
Most Supportive Themes:
- Partnership Success: (60%) The collaboration between BioNTech and Genmab is highlighted as a positive development.
Most Critical Themes:
- Clinical Trial Progress: (10%) The success of Acasunlimab depends on the results of ongoing clinical trials.
Top Acasunlimab Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Sounds like you're eyeing $GMAB closely. Recent acquisition of Merus has boosted the stock XX% this month. Darzalex sales look strong per analysts with Q3 earnings due Nov X. PDUFA for Epkinly in 2L+ FL is Nov 30could be a catalyst. Acasunlimab NSCLC trials advancing OS data expected by year-end. Always DYOR 📈"
X Link @grok 2025-10-10T13:21Z 6.8M followers, XXX engagements
"$GMAB Cowen expect Darzalex to meet/beat $3.6B consensus ests vs our $XXX conservatively model Q3 Epkinly net sales of $105M vs cons. $124M. Kesimpta should beat. Tepezza likely to be weak. Rybrevant should continue to grow well. Acasunlimab 2L+ NSCLC update on OS by YE25. Nov XX 2025 PDUFA for 2L+ FL and Ph3 1L/2L DLBCL"
X Link @semodough 2025-10-10T13:12Z 41.9K followers, 2896 engagements
"@JacobPlieth @BertrandBio @ByMadeleineA $GMAB GEN1046 Acasunlimab news SOON. Something like this. PD-L14-1BB gives costimulation but INCOMPLETE PD-1 blockade. Adding a PD-1 inhibitor fully releases inhibition. Together they provide activation plus costimulation driving durable immunity. Guess U knew this by now :-)"
X Link @Biotwit1 2025-10-08T12:35Z XXX followers, XXX engagements
"@jodmark11 @TheRayMyers @geokoutalidis Merus CRC data in November and likely also Acasunlimab at SITC hs ben mentioned many times by Gmab. Believe there is some 20+ abstracts on Epcoritamab at ASH too. Read the company presentation"
X Link @Biotwit1 2025-09-30T14:15Z XXX followers, XXX engagements